产品名称 | galectin-3 |
---|
CAS编号和信息 | rp174094 |
---|
UniProtKB | P17931 |
---|---|
Ensembl Gene | ENSG00000131981 |
Wikipedia | Galectin-3 |
ChEMBL Target | CHEMBL4531 |
Ligand ID | 6619 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
名称 | galectin-3 | ||||||||||
别名 | galectin 3 | ||||||||||
类别 | Peptide | ||||||||||
学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide | ||||||||||
生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
||||||||||
评价 |
Galectin 3 (Gal-3) is one of a group of 14 lectins that bind β-galactoside-containing carbohydrates, via a carbohydrate recognition domain (CRD), and it binds to In relation to cardiovascular disease, galectin 3/galectin 3 binding protein complexes co-localize to the leukocyte/endothelial cell interface of vein walls in mice and galectin 3 increases vein wall IL-6 levels and promotes venous thrombosis |
||||||||||
配体家族 | Galectins | ||||||||||
基因/前体 |
|
||||||||||
单字母多肽序列 | ADNFSLHDALSGSGNPNPQGWPGAWGNQPAGAGGYPGASYPGAYPGQAPPGAYPGQAPPGAYPGAPGAYPGAPAPGVYPGPPSGPGAYPSSGQPSATGAYPATGPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI | ||||||||||
三字母多肽序列 | |||||||||||
翻译后修饰 | |||||||||||
化学修饰 | |||||||||||
临床描述 |
This is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered GB1211 will be evaluated in healthy adult subjects and adult subjects with indication of suspected Nonalcoholic steatohepatitis (NASH) and liver fibrosis. |
||||||||||
来源公司 |
Galecto Biotech AB |
1. Henderson NC, Sethi T. (2009) The regulation of inflammation by galectin-3.. Immunol Rev, 230 (1): (160-71). [PMID:19594635] |
2. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. (2009) Galectin-3: a novel mediator of heart failure development and progression.. Eur J Heart Fail, 11 (9): (811-7). [PMID:19648160] |
3. Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE. (2010) GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.. Blood, 115 (19): (3939-48). [PMID:20190189] |
4. Delaine T, Collins P, MacKinnon A, Sharma G, Stegmayr J, Rajput VK, Mandal S, Cumpstey I, Larumbe A, Salameh BA et al.. (2016) Galectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition.. Chembiochem, 17 (18): (1759-70). [PMID:27356186] |
5. Harazono Y, Kho DH, Balan V, Nakajima K, Zhang T, Hogan V, Raz A. (2014) Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells.. Oncotarget, 5 (20): (9992-10001). [PMID:25393982] |
6. DeRoo EP, Wrobleski SK, Shea EM, Al-Khalil RK, Hawley AE, Henke PK, Myers DD Jr, Wakefield TW, Diaz JA. (2015) The role of galectin-3 and galectin-3-binding protein in venous thrombosis.. Blood, 125 (11): (1813-21). [PMID:25428218] |
7. Nakajima K, Kho DH, Yanagawa T, Harazono Y, Hogan V, Chen W, Ali-Fehmi R, Mehra R, Raz A. (2016) Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.. Cancer Res, 76 (6): (1391-402). [PMID:26837763] |
8. Sumida Y, Yoneda M. (2018) Current and future pharmacological therapies for NAFLD/NASH.. J Gastroenterol, 53 (3): (362-376). [PMID:29247356] |
9. Chan YC, Lin HY, Tu Z, Kuo YH, Hsu SD, Lin CH. (2018) Dissecting the Structure-Activity Relationship of Galectin-Ligand Interactions.. Int J Mol Sci, 19 (2): (1755-70). [PMID:29382172] |